News on medical imaging technologies and applications.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The study, led by researchers from precision health firm Human Longevity, also uncovered phenotypic evidence supporting some pathogenic genetic findings.
A study published this week describing the new approach shows higher resolution than an earlier method that 10x Genomics is commercializing.
With the acquisition, Luminex has expanded its offering of flow-based detection systems and broadened direct interactions with researchers conducting cellular analysis.
The deal is expected to close by the end of 2018 and to contribute between $40 million and $50 million in revenues to Luminex in 2019.
